Close

BioPharma

CDMO-Biotech Collab Diminish Business Risk In Drug Creation

Biotech companies go on to face numerous challenges, particularly while in the clinical phase of drug development, in today's fast-paced industry. The astronomically high costs, complicated manufacturing processes, as well as regulatory hurdles related to biologics can go on...

Cryoport, CGT Catapult Partner on Cell and Gene Therapies

Cryoport, Inc. , a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, and the Cell and Gene Therapy Catapult,...

Biopharma Enhancing Visibility in Connected Supply Chain

The biopharmaceutical industry, with a market value exceeding $350 billion, stands as a cornerstone of global health innovation. The emergence of the Covid-19 pandemic underscored the industry's significance and the necessity for transparent, adaptable, and interconnected supply chains. This...

Cell And Gene Therapy Market Soars, Forecasted At $82.24B

The global cell and gene therapy market has witnessed remarkable growth, with a market size of USD 15.46 billion in 2022. Projections indicate that by 2032, it could reach approximately USD 82.24 billion, showcasing a robust compound annual growth...

Biotech Innovations In The Face of Economic Uncertainty

While the pharmaceutical industry has traditionally been seen as recession-proof, with a constant demand for medicines and new treatment options, it currently faces significant challenges. Economic uncertainty is on the rise, increasing the risks associated with early drug discovery,...

Key Steps For Biopharma Startups Getting Ready For EU HTA

What is the Joint European HTA? Navigating pricing and reimbursement in the European Union (EU) can be a complex task for emerging biopharmaceutical companies (EBPs), defined as those with less than $200 million in estimated annual R&D spending or global...

Elevating Biopharmaceutical Projects With The Right CDMO

In the biopharma industry, selecting the right contract development and manufacturing organization (CDMO) is pivotal to a successful pharmaceutical development journey. This decision hinges on two critical factors: a customer-centric approach and team cohesion. In this blog, we explore...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read